选择性COX-2抑制剂对实验性大鼠胃溃疡愈合的影响
|
摘要
研究背景
NSAIDs是临床上常用的抗炎、镇痛和解热类药物,其作用的共同基础是通过抑制COX活性,阻断花生四烯酸转化为PGs。人体内主要有两种COX异构体:COX-1是结构型酶,在维持正常生理功能中起着重要作用;COX-2是诱导型酶,参与炎症、肿瘤等病理反应过程。既往认为,COX-2活性被抑制可发挥抗炎、镇痛和解热作用,而COX-1活性被抑制则会产生一系列副作用。传统的NSAIDs为非选择性COX抑制剂,同时作用于COX-1和COX-2,在发挥治疗作用的同时,胃肠道副作用也很明显。选择性COX-2抑制剂是近年出现的新型NSAIDs,被认为药理作用强,胃肠道副作用低。但选择性COX-2抑制剂的胃肠道安全性是否真如大家期望的那样高,这一点尚存有争议。近来有研究者发现,这类药物可能同传统的NSAIDs一样,也会影响胃溃疡的愈合,但其机制目前尚不明了。研究表明,胃溃疡的愈合与胃酸分泌、胃粘膜上皮细胞增殖、溃疡底部微血管形成及ERK信号转导通路的激活等环节密切相关。
目的和意义
本研究以乙酸性大鼠胃溃疡模型为基础,旨在明确以下几个方面的问题:1、选择性COX-2抑制剂对胃溃疡愈合及胃组织PGs代谢有何影响;2、从胃酸分泌、胃粘膜上皮细胞增殖以及溃疡底部微血管形成的角度探讨选择性COX-2抑制剂延缓胃溃疡愈合的机制;3、探讨选择性COX-2抑制剂对与胃酸分泌密切相关的H~+,K~+-ATPase,与上皮细胞增殖有关的HGF及其受体c-Met,与微血
BACKGROUNDNSAIDs are medications used primarily to treat inflammation, pain, and fever. NSAIDs work by blocking the conversion of arachidonic acid to PGs through inhibiting COX activity. There are two isoforms of COX, denoted COX-1 and COX-2. The former is constitutive and essential for the maintenance of normal physiological function. The latter is inductive, participating in some pathological processes such as inflammation, tumor, etc. It was once considered that NSAIDs exerted the function to treat inflammation, pain, and fever via inhibiting COX-2 activity, and brought a series of side effects via inhibiting COX-1 activity. Conventional NSAIDs are nonselective COX inhibitor, inhibiting the activity of both COX-1 and COX-2, the gastrointestinal side effects of which are noticeable. Selective COX-2 inhibitor is a new type of NSAIDs explored in the recent years. It has potent therapeutic efficacy and low gastrointestinal side effects, and is proven effective to some tumors and cardiovascular diseases. But there are still many arguments regarding whether the gastrointestinal safety of selective COX-2 inhibitor is as high as people expect. Some researchers reported lately that it delayed the healing of gastric ulcer as conventional NSAIDs. Studies have shown that the healing of gastric ulcer is closely related to gastric acid secretion, gastric epithelial cell proliferation, angiogenesis at the ulcer base, and activation of ERK signal transduction pathway.
AIMSThrough observing the effects of the selective COX-2 inhibitor, celecoxib, on the healing of acetic acid-induced rat gastric ulcer, the study was aimed to: 1) determine whether selective COX-2 inhibitor affects gastric ulcer healing and PGs metabolization in gastric tissue; 2) evaluate the effects of selective COX-2 inhibitor on gastric acid secretion, gastric epithelial cell proliferation, angiogenesis at the ulcer base; 3) explore the effects of selective COX-2 inhibitor on the expression of H% K+ - ATPase, HGF and its receptor c-Met, bFGF and its receptor bFGFR, which are respectively related to gastric acid secretion, gastric epithelial cell proliferation and angiogenesis at the ulcer base, hoping to elucidate the mechanisms of selective COX-2 inhibitor delaying gastric ulcer healing at molecular levels; 4) investigate the effects of selective COX-2 inhibitor on ERK pathway, hoping to elucidate the mechanisms of selective COX-2 inhibitor delaying gastric ulcer healing from the angle of signal transduction.MATERIALS AND METHODS1. Grouping of experimental animals: 48 Wistar rats were randomly divided into model group and sham-operation group with 40 and 8 rats, respectively. Sham-operation group serves as normal control. Model group underwent the operation to produce acetic acid-induced gastric ulcer. Sham-operation group underwent sham operation. 3 days after the operation, all rats of sham-operation group and 8 rats of model group were euthanized. 32 residual rats in model group were divided into celecoxib group and NS group randomly and averagely. Celecoxib group received intragastric perfusion with 0.2% celecoxib solution, and NS group with 0.9% NaCl solution starting 3 days after ulcer induction. Rats in celecoxib group and NS group were euthanized at 6 and 9 days after ulcer induction (8 rats in each group at each time point).2. The gross structure of rat stomach was observered. The ulcer margin was drawn on a cellophane paper to measure the ulcer area using a 1 mm graph paper.
The rat gastric content was collected and centrifuged, and the obtained superntant was gastric juice. The titre amount of gastric acid was determined with 0.01 mol/L NaOH, and the total acidity of gastric juice was calculated.3. A 3mm X 5mm tissue strip including the ulcer base and both sides of the ulcer margin was taken and fixed in 4% paraformaldehyde solution to make paraffin sections for H&E staining and for immunohistochemical staining of COX-1, COX-2, PCNA, and vWF. PCNA LI and microvessel number were respectively counted after PCNA and vWF immunohistochemical staining.4. A sample of gastric tissue weighed about 150 mg was taken from the ulcer base and the ulcer margin. A half was used to measure COX activity and PGE2 content by ELISA, and the other half was used to measure the mRNA expression of H+, K+-ATPase, bFGF, bFGFR by RT-PCR as well as the protein expression of COX-1, COX-2, HGF, c-Met, p-raf-1, and p-ERK by Western Blotting.5. A lmmX5mm tissue strip including the ulcer margin was taken from 4 rats in each group, and immediately fixed in 2% Glutaraldehyde solution for the examination under transmission electron microscope to observe the ulreastructure of parietal cell.RESULTS1. Effect of celecoxib on the healing of gastric ulcerThe ulcer area 3 days after ulcer induction was 33.3 + 7.4 mm2. 6 days after ulcer induction, the ulcer area was significantly decreased(versus 3 days) to 24.5 ± 6.4 mm2 in NS group, and slightly but not significantly decreased(versus 3 days) to 28.0 + 5.2 mm2 in celecoxib group. There was no significant difference between the two groups at 6 days after ulcer induction. 9 days after ulcer induction, the ulcer area was respectively 11.9 + 3.1 mm2 and 19.7 + 3.8mm2 in NS group and celecoxib group, which was significantly decreased(versus 3 days) in both groups. However, the ulcer area in celecoxib group was nearly 1.7-fold larger than in NS group (P<0.01) , demonstrating that celecoxib treatment significantly delays gastric ulcer
healing.2. Effects of celecoxib on PGs metabolism in ulcerated rat gastric tissue(1) Changes in the expression of COX-1 and COX-2 after ulcer inductionIn normal rat gastric mucosa, strong COX-1 immunohistochemical staining signal was detected predominantly in chief cells and parietal cells located in the lower 2/3 mucosa. 3 days after ulcer induction, the distribution of COX-1 signal and the number of positive cells in the gastric mucosa at the ulcer margin were similar to that of normal rat. Only faint COX-2 signal was detected in normal rat gastric mucosa. 3 days after ulcer induction, robust COX-2 signal was present in gastric epithelial cells and parietal cells in the gastric mucosa at the ulcer margin. Western Blotting analysis showed that there were relatively high COX-1 and very low COX-2 protein expression in normal rat gastric tissue. 3 days after ulcer induction, COX-2 protein level in ulcerated tissue was increased 10.8-fold, but COX-1 protein level in ulcerated tissue changed little, versus normal rat gastric tissue.(2) Effects of celecoxib on COX activity and PGE2 content3 days after ulcer induction, COX activity and PGE2 content in ulcerated tissue were increased about 4-fold and 6-fold, respectively, versus normal rat gastric tissue. COX activity and PGE2 content in NS group changed little at 6 and 9 days versus 3 days after ulcer induction. COX activity and PGE2 content in celecoxib group were significantly lower than in NS group at both 6 and 9 days after ulcer induction3. Effect of celecoxib on gastric acid secretion in gastric ulcerated rat(1) Effect of celecoxib on total acidity of gastric juiceThe total acidity of gastric juice in normal rat was 14.8 ±3.4 mmol /L. 3 days after ulcer induction, the total acidity of gastric juice was significantly decreased (versus normal rat) to 6.4+1.5 mmol/L. 6 and 9 days after ulcer induction, the total acidity of gastric juice in NS group was similar to 3 days, while that in celecoxib group was significantly increased(versus 3 days) to 10.6±3.1mmol/L and 12.5 + 2.2
mmol/L, respectively. The total acidity of gastric juice in celecoxib group was significantly higher than that in NS group at both 6 and 9 days after ulcer induction (P<0.05, P<0.01).(2) Effect of celecoxib on H*, K+-ATPase mRNA expression￡T\ K+-ATPase mRNA level was significantly decreased at 3 days after ulcer induction, only 37% of that in normal rat. 6 and 9 days after ulcer induction, IT1", K+-ATPase mRNA level in NS group was similar to 3 days, while that in celecoxib group was significantly increased (versus 3 days). H+, K+-ATPase mRNA level in celecoxib group was significantly higher than that in NS group at both 6 and 9 days after ulcer induction (P<0.01).(3) Effect of celecoxib on the ultrastructure of parietal cellThere was plenty of mitochondrias and some secretary canaliculuses with a lot of microvilluses in parietal cell cytoplasm of normal rat, indicating the function of gastric acid secretion was active. 3 days after ulcer induction, parietal cell at the ulcer margin had such changes as fewer secretary canaliculuses, sparser microvilluses, and more tubulovesicular systems than in normal rat, indicating the function of gastric acid secretion was inactive. The amount of secretary canaliculus and microvillus were increased {versus 3 days) in both NS group and celecoxib group at 6 and 9 days after ulcer induction, but there weren' t distinct difference between the two groups.4. Effect of celecoxib on gastric epithelial cell proliferation in ulcerated rat(1) Effect of celecoxib on PCNA expressionIn normal rat gastric mucosa, PCNA immunohistochemical staining signal was present mainly in the glandular epithelial cells of gastric pits, and PCNA-positive cells constituted proliferative cell zone. After ulcer induction, the amount of PCNA-positive cells in the gastric mucosa at the ulcer margin was increased, and the proliferative cell zone became broader than that in normal rat. Quantitative analysis showed that the PCNA LI in normal rat was 11.2 + 2.8%. 3 days after ulcer induction,
the PCNA LI was significantly increased to 16.4 + 2.3%. 6 and 9 days after ulcer induction, the PCNA LI in NS group was higher than 3 days, while that in celecoxib group was similar to 3 days. The PCNA LI in celecoxib group was significantly lower than that in NS group at both 6 and 9 days after ulcer induction (P<0.05, P<0.01).(2) Effects of celecoxib on protein expression of HGF and c-Met Western Blotting analysis showed that the protein levels of HGF and c-Met in ulcerated tissue were respectively increased 4.5-fold and 1.8-fold (versus normal rat) 3 days after ulcer induction. HGF protein level in both NS group and celecoxib group changed little at 6 and 9 days versus 3 days after ulcer induction, and there was no significantly difference between the two groups at either time point. 6 and 9 days after ulcer induction, the protein level of c-Met in NS group was significantly increased (versus 3 days), while that in celecoxib group was similar to 3 days. The protein level of c-Met in celecoxib group was significantly lower than that in NS group at both 6 and 9 days after ulcer induction (P<0.01). 5. Effect of celecoxib on angiogenesis at the ulcer base(1) Effect of celecoxib on the number of micro vessels at the ulcer baseThe number of microvessels was respectively 28.5±5.9/field and 23.1±5.8/field in NS group and celecoxib group at 6 days after ulcer induction, and there was no significant difference between the two groups. 9 days after ulcer induction, the number of microvessels was respectively 42.9±6.8/field and 30.6 + 6.2/field in NS group and celecoxib group, and the difference between the two groups was significant(P<0.01).(2) Effect of celecoxib on mRNA expression of bFGF and bFGFRLittle expression of bFGF and bFGFR mRNA was detected in normal rat gastric tissue. The mRNA levels of bFGF and bFGFR in ulcerated tissue were respectively increased 6.0-fold and 4.6-fold (versus normal rat) 3 days after ulcer induction. 6 and 9 days after ulcer induction, the mRNA levels of bFGF and bFGFR
in NS group were significantly increased (versus 3 days), while those in celecoxib group changed little (versus 3 days). The mRNA levels of bFGF and bFGFR in celecoxib group were significantly lower than in NS group at 9 days after ulcer induction (/><0.01).6. Effects of celecoxib on protein levels of p-raf-1 and p-ERK in ulcerated rat gastric tissueThere were relatively low protein levels of p-raf-1 and p-ERK in normal rat gastric tissue. The protein levels of p-raf-1 and p-ERK in ulcerated tissue were respectively increased 5.4-fold and 7.1-fold (versus normal rat) 3 days after ulcer induction. 6 and 9 days after ulcer induction, the protein levels of p-raf-1 and p-ERK in NS group changed little (versus 3 days), while those in celecoxib group were significantly decreased (versus 3 days). At both 6 and 9 days after ulcer induction, the protein levels of p-raf-1 and p-ERK in celecoxib group were significantly lower than those in NS group. CONCLUSION1. Selective COX-2 inhibitor delays the healing of acetic acid-induced rat gastric ulcer, and decreases PGs content in gastric tissue, demonstrating that COX-2 derived PGs have essentially promotive action on the healing of acetic acid-induced rat gastric ulcer.2. The expression of H+, K+-ATPase mRNA and gastric acid secretion are significantly decreased during the healing of acetic acid-induced rat gastric ulcer. Selective COX-2 inhibitor can intensify gastric acid secretion through upregulating the expression of H+, K+-ATPase mRNA in parietal cell of gastric ulcerated rat, suggesting that strengthening the digestive action on newly formed granulation tissue at the ulcer base through intensifying gastric acid secretion may be one of its mechanisms to delay the healing of acetic acid-induced rat gastric ulcer.3. The protein expression of HGF and its receptor c-Met related to gastric epithelial cell proliferation as well as the mRNA expression of bFGF and its receptor
bFGFR related to angiogenesis in gastric tissue are significantly upregulated during the healing of acetic acid-induced rat gastric ulcer. Selective COX-2 inhibitor can inhibit gastric epithelial cell proliferation through downregulating the protein expression of c-Met, inhibit angiogenesis in granulation tissue at ulcer base through downregulating the mRNA expression of bFGF and bFGFR, thereby delay the healing of acetic acid-induced rat gastric ulcer.4. Selective COX-2 inhibitor can significantly decrease the protein levels of p-raf-1 and p-ERK in ulcerated rat gastric tissue, indicating that selective COX-2 inhibitor may delay gastric ulcer healing through inhibiting the activation of raf-1/ERK signal transduction pathway.
NSAIDs是临床上常用的抗炎、镇痛和解热类药物,其作用的共同基础是通过抑制COX活性,阻断花生四烯酸转化为PGs。人体内主要有两种COX异构体:COX-1是结构型酶,在维持正常生理功能中起着重要作用;COX-2是诱导型酶,参与炎症、肿瘤等病理反应过程。既往认为,COX-2活性被抑制可发挥抗炎、镇痛和解热作用,而COX-1活性被抑制则会产生一系列副作用。传统的NSAIDs为非选择性COX抑制剂,同时作用于COX-1和COX-2,在发挥治疗作用的同时,胃肠道副作用也很明显。选择性COX-2抑制剂是近年出现的新型NSAIDs,被认为药理作用强,胃肠道副作用低。但选择性COX-2抑制剂的胃肠道安全性是否真如大家期望的那样高,这一点尚存有争议。近来有研究者发现,这类药物可能同传统的NSAIDs一样,也会影响胃溃疡的愈合,但其机制目前尚不明了。研究表明,胃溃疡的愈合与胃酸分泌、胃粘膜上皮细胞增殖、溃疡底部微血管形成及ERK信号转导通路的激活等环节密切相关。
目的和意义
本研究以乙酸性大鼠胃溃疡模型为基础,旨在明确以下几个方面的问题:1、选择性COX-2抑制剂对胃溃疡愈合及胃组织PGs代谢有何影响;2、从胃酸分泌、胃粘膜上皮细胞增殖以及溃疡底部微血管形成的角度探讨选择性COX-2抑制剂延缓胃溃疡愈合的机制;3、探讨选择性COX-2抑制剂对与胃酸分泌密切相关的H~+,K~+-ATPase,与上皮细胞增殖有关的HGF及其受体c-Met,与微血
BACKGROUNDNSAIDs are medications used primarily to treat inflammation, pain, and fever. NSAIDs work by blocking the conversion of arachidonic acid to PGs through inhibiting COX activity. There are two isoforms of COX, denoted COX-1 and COX-2. The former is constitutive and essential for the maintenance of normal physiological function. The latter is inductive, participating in some pathological processes such as inflammation, tumor, etc. It was once considered that NSAIDs exerted the function to treat inflammation, pain, and fever via inhibiting COX-2 activity, and brought a series of side effects via inhibiting COX-1 activity. Conventional NSAIDs are nonselective COX inhibitor, inhibiting the activity of both COX-1 and COX-2, the gastrointestinal side effects of which are noticeable. Selective COX-2 inhibitor is a new type of NSAIDs explored in the recent years. It has potent therapeutic efficacy and low gastrointestinal side effects, and is proven effective to some tumors and cardiovascular diseases. But there are still many arguments regarding whether the gastrointestinal safety of selective COX-2 inhibitor is as high as people expect. Some researchers reported lately that it delayed the healing of gastric ulcer as conventional NSAIDs. Studies have shown that the healing of gastric ulcer is closely related to gastric acid secretion, gastric epithelial cell proliferation, angiogenesis at the ulcer base, and activation of ERK signal transduction pathway.
AIMSThrough observing the effects of the selective COX-2 inhibitor, celecoxib, on the healing of acetic acid-induced rat gastric ulcer, the study was aimed to: 1) determine whether selective COX-2 inhibitor affects gastric ulcer healing and PGs metabolization in gastric tissue; 2) evaluate the effects of selective COX-2 inhibitor on gastric acid secretion, gastric epithelial cell proliferation, angiogenesis at the ulcer base; 3) explore the effects of selective COX-2 inhibitor on the expression of H% K+ - ATPase, HGF and its receptor c-Met, bFGF and its receptor bFGFR, which are respectively related to gastric acid secretion, gastric epithelial cell proliferation and angiogenesis at the ulcer base, hoping to elucidate the mechanisms of selective COX-2 inhibitor delaying gastric ulcer healing at molecular levels; 4) investigate the effects of selective COX-2 inhibitor on ERK pathway, hoping to elucidate the mechanisms of selective COX-2 inhibitor delaying gastric ulcer healing from the angle of signal transduction.MATERIALS AND METHODS1. Grouping of experimental animals: 48 Wistar rats were randomly divided into model group and sham-operation group with 40 and 8 rats, respectively. Sham-operation group serves as normal control. Model group underwent the operation to produce acetic acid-induced gastric ulcer. Sham-operation group underwent sham operation. 3 days after the operation, all rats of sham-operation group and 8 rats of model group were euthanized. 32 residual rats in model group were divided into celecoxib group and NS group randomly and averagely. Celecoxib group received intragastric perfusion with 0.2% celecoxib solution, and NS group with 0.9% NaCl solution starting 3 days after ulcer induction. Rats in celecoxib group and NS group were euthanized at 6 and 9 days after ulcer induction (8 rats in each group at each time point).2. The gross structure of rat stomach was observered. The ulcer margin was drawn on a cellophane paper to measure the ulcer area using a 1 mm graph paper.
The rat gastric content was collected and centrifuged, and the obtained superntant was gastric juice. The titre amount of gastric acid was determined with 0.01 mol/L NaOH, and the total acidity of gastric juice was calculated.3. A 3mm X 5mm tissue strip including the ulcer base and both sides of the ulcer margin was taken and fixed in 4% paraformaldehyde solution to make paraffin sections for H&E staining and for immunohistochemical staining of COX-1, COX-2, PCNA, and vWF. PCNA LI and microvessel number were respectively counted after PCNA and vWF immunohistochemical staining.4. A sample of gastric tissue weighed about 150 mg was taken from the ulcer base and the ulcer margin. A half was used to measure COX activity and PGE2 content by ELISA, and the other half was used to measure the mRNA expression of H+, K+-ATPase, bFGF, bFGFR by RT-PCR as well as the protein expression of COX-1, COX-2, HGF, c-Met, p-raf-1, and p-ERK by Western Blotting.5. A lmmX5mm tissue strip including the ulcer margin was taken from 4 rats in each group, and immediately fixed in 2% Glutaraldehyde solution for the examination under transmission electron microscope to observe the ulreastructure of parietal cell.RESULTS1. Effect of celecoxib on the healing of gastric ulcerThe ulcer area 3 days after ulcer induction was 33.3 + 7.4 mm2. 6 days after ulcer induction, the ulcer area was significantly decreased(versus 3 days) to 24.5 ± 6.4 mm2 in NS group, and slightly but not significantly decreased(versus 3 days) to 28.0 + 5.2 mm2 in celecoxib group. There was no significant difference between the two groups at 6 days after ulcer induction. 9 days after ulcer induction, the ulcer area was respectively 11.9 + 3.1 mm2 and 19.7 + 3.8mm2 in NS group and celecoxib group, which was significantly decreased(versus 3 days) in both groups. However, the ulcer area in celecoxib group was nearly 1.7-fold larger than in NS group (P<0.01) , demonstrating that celecoxib treatment significantly delays gastric ulcer
healing.2. Effects of celecoxib on PGs metabolism in ulcerated rat gastric tissue(1) Changes in the expression of COX-1 and COX-2 after ulcer inductionIn normal rat gastric mucosa, strong COX-1 immunohistochemical staining signal was detected predominantly in chief cells and parietal cells located in the lower 2/3 mucosa. 3 days after ulcer induction, the distribution of COX-1 signal and the number of positive cells in the gastric mucosa at the ulcer margin were similar to that of normal rat. Only faint COX-2 signal was detected in normal rat gastric mucosa. 3 days after ulcer induction, robust COX-2 signal was present in gastric epithelial cells and parietal cells in the gastric mucosa at the ulcer margin. Western Blotting analysis showed that there were relatively high COX-1 and very low COX-2 protein expression in normal rat gastric tissue. 3 days after ulcer induction, COX-2 protein level in ulcerated tissue was increased 10.8-fold, but COX-1 protein level in ulcerated tissue changed little, versus normal rat gastric tissue.(2) Effects of celecoxib on COX activity and PGE2 content3 days after ulcer induction, COX activity and PGE2 content in ulcerated tissue were increased about 4-fold and 6-fold, respectively, versus normal rat gastric tissue. COX activity and PGE2 content in NS group changed little at 6 and 9 days versus 3 days after ulcer induction. COX activity and PGE2 content in celecoxib group were significantly lower than in NS group at both 6 and 9 days after ulcer induction3. Effect of celecoxib on gastric acid secretion in gastric ulcerated rat(1) Effect of celecoxib on total acidity of gastric juiceThe total acidity of gastric juice in normal rat was 14.8 ±3.4 mmol /L. 3 days after ulcer induction, the total acidity of gastric juice was significantly decreased (versus normal rat) to 6.4+1.5 mmol/L. 6 and 9 days after ulcer induction, the total acidity of gastric juice in NS group was similar to 3 days, while that in celecoxib group was significantly increased(versus 3 days) to 10.6±3.1mmol/L and 12.5 + 2.2
mmol/L, respectively. The total acidity of gastric juice in celecoxib group was significantly higher than that in NS group at both 6 and 9 days after ulcer induction (P<0.05, P<0.01).(2) Effect of celecoxib on H*, K+-ATPase mRNA expression￡T\ K+-ATPase mRNA level was significantly decreased at 3 days after ulcer induction, only 37% of that in normal rat. 6 and 9 days after ulcer induction, IT1", K+-ATPase mRNA level in NS group was similar to 3 days, while that in celecoxib group was significantly increased (versus 3 days). H+, K+-ATPase mRNA level in celecoxib group was significantly higher than that in NS group at both 6 and 9 days after ulcer induction (P<0.01).(3) Effect of celecoxib on the ultrastructure of parietal cellThere was plenty of mitochondrias and some secretary canaliculuses with a lot of microvilluses in parietal cell cytoplasm of normal rat, indicating the function of gastric acid secretion was active. 3 days after ulcer induction, parietal cell at the ulcer margin had such changes as fewer secretary canaliculuses, sparser microvilluses, and more tubulovesicular systems than in normal rat, indicating the function of gastric acid secretion was inactive. The amount of secretary canaliculus and microvillus were increased {versus 3 days) in both NS group and celecoxib group at 6 and 9 days after ulcer induction, but there weren' t distinct difference between the two groups.4. Effect of celecoxib on gastric epithelial cell proliferation in ulcerated rat(1) Effect of celecoxib on PCNA expressionIn normal rat gastric mucosa, PCNA immunohistochemical staining signal was present mainly in the glandular epithelial cells of gastric pits, and PCNA-positive cells constituted proliferative cell zone. After ulcer induction, the amount of PCNA-positive cells in the gastric mucosa at the ulcer margin was increased, and the proliferative cell zone became broader than that in normal rat. Quantitative analysis showed that the PCNA LI in normal rat was 11.2 + 2.8%. 3 days after ulcer induction,
the PCNA LI was significantly increased to 16.4 + 2.3%. 6 and 9 days after ulcer induction, the PCNA LI in NS group was higher than 3 days, while that in celecoxib group was similar to 3 days. The PCNA LI in celecoxib group was significantly lower than that in NS group at both 6 and 9 days after ulcer induction (P<0.05, P<0.01).(2) Effects of celecoxib on protein expression of HGF and c-Met Western Blotting analysis showed that the protein levels of HGF and c-Met in ulcerated tissue were respectively increased 4.5-fold and 1.8-fold (versus normal rat) 3 days after ulcer induction. HGF protein level in both NS group and celecoxib group changed little at 6 and 9 days versus 3 days after ulcer induction, and there was no significantly difference between the two groups at either time point. 6 and 9 days after ulcer induction, the protein level of c-Met in NS group was significantly increased (versus 3 days), while that in celecoxib group was similar to 3 days. The protein level of c-Met in celecoxib group was significantly lower than that in NS group at both 6 and 9 days after ulcer induction (P<0.01). 5. Effect of celecoxib on angiogenesis at the ulcer base(1) Effect of celecoxib on the number of micro vessels at the ulcer baseThe number of microvessels was respectively 28.5±5.9/field and 23.1±5.8/field in NS group and celecoxib group at 6 days after ulcer induction, and there was no significant difference between the two groups. 9 days after ulcer induction, the number of microvessels was respectively 42.9±6.8/field and 30.6 + 6.2/field in NS group and celecoxib group, and the difference between the two groups was significant(P<0.01).(2) Effect of celecoxib on mRNA expression of bFGF and bFGFRLittle expression of bFGF and bFGFR mRNA was detected in normal rat gastric tissue. The mRNA levels of bFGF and bFGFR in ulcerated tissue were respectively increased 6.0-fold and 4.6-fold (versus normal rat) 3 days after ulcer induction. 6 and 9 days after ulcer induction, the mRNA levels of bFGF and bFGFR
in NS group were significantly increased (versus 3 days), while those in celecoxib group changed little (versus 3 days). The mRNA levels of bFGF and bFGFR in celecoxib group were significantly lower than in NS group at 9 days after ulcer induction (/><0.01).6. Effects of celecoxib on protein levels of p-raf-1 and p-ERK in ulcerated rat gastric tissueThere were relatively low protein levels of p-raf-1 and p-ERK in normal rat gastric tissue. The protein levels of p-raf-1 and p-ERK in ulcerated tissue were respectively increased 5.4-fold and 7.1-fold (versus normal rat) 3 days after ulcer induction. 6 and 9 days after ulcer induction, the protein levels of p-raf-1 and p-ERK in NS group changed little (versus 3 days), while those in celecoxib group were significantly decreased (versus 3 days). At both 6 and 9 days after ulcer induction, the protein levels of p-raf-1 and p-ERK in celecoxib group were significantly lower than those in NS group. CONCLUSION1. Selective COX-2 inhibitor delays the healing of acetic acid-induced rat gastric ulcer, and decreases PGs content in gastric tissue, demonstrating that COX-2 derived PGs have essentially promotive action on the healing of acetic acid-induced rat gastric ulcer.2. The expression of H+, K+-ATPase mRNA and gastric acid secretion are significantly decreased during the healing of acetic acid-induced rat gastric ulcer. Selective COX-2 inhibitor can intensify gastric acid secretion through upregulating the expression of H+, K+-ATPase mRNA in parietal cell of gastric ulcerated rat, suggesting that strengthening the digestive action on newly formed granulation tissue at the ulcer base through intensifying gastric acid secretion may be one of its mechanisms to delay the healing of acetic acid-induced rat gastric ulcer.3. The protein expression of HGF and its receptor c-Met related to gastric epithelial cell proliferation as well as the mRNA expression of bFGF and its receptor
bFGFR related to angiogenesis in gastric tissue are significantly upregulated during the healing of acetic acid-induced rat gastric ulcer. Selective COX-2 inhibitor can inhibit gastric epithelial cell proliferation through downregulating the protein expression of c-Met, inhibit angiogenesis in granulation tissue at ulcer base through downregulating the mRNA expression of bFGF and bFGFR, thereby delay the healing of acetic acid-induced rat gastric ulcer.4. Selective COX-2 inhibitor can significantly decrease the protein levels of p-raf-1 and p-ERK in ulcerated rat gastric tissue, indicating that selective COX-2 inhibitor may delay gastric ulcer healing through inhibiting the activation of raf-1/ERK signal transduction pathway.
引文
1. Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Acad Sci USA, 1991, 88(6): 2692-2696
2. Kim KM, Oh YL, Ko JS, et al. Histopathology and expression of Ki-67 and cyclooxygenase-2 in childhood Helicobacter pylori gastritis. J Gastroenterol, 2004, 39(3): 231-237
3. Kuo CL, Chi CW, Liu TY. Modulation of apoptosis by berberine through inhibition of cyclooxygenase-2 and Mcl-1 expression in oral cancer cells. In Vivo, 2005, 19(1): 247-252
4. Tibble J, Sigthorsson G, Caldwell C, et al. Effects of NSAIDs on cryoprobe-induced gastric ulcer healing in rats. Aliment Pharmacol Ther, 2001, 15(12): 2001-2008
5. Peura DA. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med, 2004, 117 Suppl 5A: 63S-71S
6. Gajraj NM, Joshi GP. Role of cyclooxygenase-2 inhibitors in postoperative pain management. Anesthesiol Clin North America, 2005, 23(1): 49-72
7. Stephens JM, Pashos CL, Haider S, et al. Making progress in the management of postoperative pain: a review of the cyclooxygenase 2-specific inhibitors. Pharmacotherapy, 2004, 24(12): 1714-1731
8. Qadri SS, Wang JH, Coffey JC, et al. Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition. Ann Thorac Surg, 2005, 79(3): 990-995
9. Tanaka T, Delong PA, Amin K, et al. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery. Ann Surg, 2005, 241(1): 168-178
10. Graham P, Pidgeon GP, Tamosiuniene R, et al. Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation, 2004, 110(17): 2701-2707
11. Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum, 2002, 32(3 Suppl 1): 25-32
12. Schmassmann A, Peskar BM, Stettler C, et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol, 1998, 123(5): 795-804
13. Giap AQ, Tarnawski A, Hoa NT, et al. NSAID inhibition of RGM1 gastric monolayer wound re-epithelialization: comparison of selective Cox-2 versus non-selective Cox inhibitors. Life Sci, 2002, 70(25): 3029-3037
14. Berenguer B, Alarcon de la Lastra C, Moreno FJ. Chronic gastric ulcer healing in rats subjected to selective and non-selective cyclooxygenase-2 inhibitors. Eur J Pharmacol, 2002; 442(1-2): 125-135
15. Helander HF, Weijdegard B, Bamberg K, et al. The expression of pepsinogen c mRNA in normal gastroduodenal mucosa and the gastric ulcer margin of the rat. Histochem Cell Biol, 1996, 105(2): 163-169
16. Kazumori H, Ishihara S, Fukuda R. Time-course changes of ECL cell markers in acetic acid-induced gastric ulcers in rats. Aliment Pharmacol Ther, 2002, 16 Suppl 2: 10-19
17. Tsukimi Y, Nakai H, Itoh S, et al. Involvement of heat shock proteins in the healing of acetic acid-induced gastric ulcers in rats. J Physiol Pharmacol, 2001, 52(3): 391-406
18. Konturek PC. Brzozowski T, Sulekova Z, et al. Role of leptin in ulcer healing. Eur J Pharmacol, 2001, 414(1): 87-97
19. Nguyen NV, Gleeson PA, Courtois-Coutry N, et al. Gastric parietal cell acid secretion in mice can be regulated independently of H/K ATPase endocytosis. Gastroenterology, 2004, 127(1): 145-154
20. Barocelli E, Ballabeni V. Histamine in the control of gastric acid secretion: a topic review. Pharmacol Res, 2003,47(4): 299-304
21. Chen D, Zhao CM, Hakanson R, et al. Altered control of gastric acid secretion in gastrin-cholecystokinin double mutant mice. Gastroenterology, 2004, 126(2): 476-487
22. Fykse V, Coy DH, Waldum HL, et al. Somatostatin-receptor 2 (sst2)-mediated effects of endogenous somatostatin on exocrine and endocrine secretion of the rat stomach. Br J Pharmacol, 2005, 144(3): 416-421
23. Beales IL, Calam J. Inhibition of carbachol stimulated acid secretion by interleukin 1beta in rabbit parietal cells requires protein kinase C. Gut, 2001, 48(6): 782-789
24. Schmassmann A, Stettler C, Poulsom R, et al. Roles of hepatocyte growth factor and its receptor Met during gastric ulcer healing in rats. Gastroenterology, 1997, 113(6): 1858-1872
25. Ma L, Chow JY, Wong BC, et al. Role of capsaicin sensory nerves and EGF in the healing of gastric ulcer in rats. Life Sci, 2000, 66(15): PL213-220
26. Gonul B, Akbulut KG, Ozer C, et al. The role of transforming growth factor alpha formulation on aspirin-induced ulcer healing and oxidant stress in the gastric mucosa. Surg Today, 2004, 34(12): 1035-1040
27. Hori K, Shiota G, Kawasaki H. Expression of hepatocyte growth factor and c-met receptor in gastric mucosa during gastric ulcer healing. Scand J Gastroenterol, 2000,35(1):23-31
28. Brzozowski T, Konturek PC, Konturek SJ, et al. Effect of local application of growth factors on gastric ulcer healing and mucosal expression of cyclooxygenase-1 and -2. Digestion, 2001, 64(1): 15-29
29. Szabo S, Khomenko T, Gombos Z, et al. Review article: transcription factors and growth factors in ulcer healing. Aliment Pharmacol Ther, 2000, 14 Suppl 1: 33-43
30. Shih SC, Tseng KW, Lin SC, et al. Expression patterns of transforming growth factor-beta and its receptors in gastric mucosa of patients with refractory gastric ulcer. World J Gastroenterol, 2005, 11(1): 136-141
31. Szabo S, Vincze A. Growth factors in ulcer healing: lessons from recent studies. J Physiol Paris, 2000, 94(2): 77-81
32. Li DY, Zhao K, Zhou JF, et al. Changes of expressions of VEGE bFGF, and angiogenesis, and effect of benazepril, bFGF on angiogenesis in acute myocardial infarction model of the rabbits. Biomed Environ Sci, 2004, 17(4): 442-451
33. Shin HY, Schwartz EA, Bizios R, et al. Receptor-mediated basic fibroblast growth factor signaling regulates cyclic pressure-induced human endothelial cell proliferation. Endothelium, 2004, 11 (5-6): 285-291
34. Kawanaka H, Tomikawa M, Jones MK, et al. Portal hypertensive gastric mucosa has reduced activation of MAP kinase (ERK2) in response to alcohol injury: a key to impaired healing? FASEB J, 2001, 15(3): 574-576
35. Pai R, Ohta M, Itani RM, et al. Induction of mitogen-activated protein kinase signal transducfion pathway during gastric ulcer healing in rats. Gastroenterology, 1998, 114(4): 706-713
36. Schmassmann A. Mechanisms of ulcer healing and effects of nonsteroidal anti-inflammatory drugs. Am J Med, 1998, 104(3A): 43S-51S
37. Brzozowski T. Experimental production of peptic ulcer, gastric damage and cancer models and their use in pathophysiological studies and pharmacological treatment-Polish achievements. J Physiol Pharmacol, 2003, 54 Suppl 3: 99-126
38. Wallace JL, Chapman K, McKnight W. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol, 1999, 126: 1200-1204
39.孙凤蓬,宋于刚,朱新生等.冰乙酸性大鼠胃溃疡模型制作及溃疡自愈过程中胃窦的组织学.第一军医大学学报,200l,21(8):578-581
40. Calabro A, Grappone C, Pellegrini G; et al. Spatial and temporal pattern of expression of interstitial collagenase, stromelysin/transin, gelatinase A, and TIMP-1 during experimental gastric ulcer healing. Digestion, 2004, 70(2): 127-138
41. Kim JS, Kim JM, Jung HC, et al. Helicobacter pylori down-regulates the receptors of vascular endothelial growth factor and angiopoietin in vascular endothelial cells: implications in the impairment of gastric ulcer healing. Dig Dis Sci, 2004, 49(5): 778-786
42.朱立,杨宗诚,黎螯等.大鼠严重烧伤早期胃酸分泌功能改变的机制及其在急性胃粘膜损害防治中的意义.中华普通外科杂志,2000,15(2):88-90
43.郭津生,古永亮,王吉耀等.环氧化酶异构酶在大鼠胃溃疡模型中的表达和活性变化.中华医学杂志,2001,81(24):1519-1522
44. Tsujii M, Kawano S, Tsuji S, et al. Cell kinetics of mucosal atrophy in rat stomach induced by long-term administration of ammonia. Gastroenterology, 1993, 104(3): 796-801
45.叶秀锦,王丽君,林茂芳等.急性白血病患者骨髓血管新生的研究及临床意义.中华内科杂志,2003,42(7):486-489
46. Chung NA, Beevers DG Lip G. Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. Blood Press, 2004, 13(3): 183-189
47. Yang DH, Tsuyama S, Murata E The expression of gastric H+-K+-ATPase mRNA and protein in developing rat fundic gland. Histochem J, 2001, 33(3): 159-166
48. de Groot M, Schuurs TA, Leuvenink HG, et al. Macrophage overgrowth affects neighboring nonovergrown encapsulated islets. J Surg Res, 2003, 115(2): 235-241
49. Tomlinson A, Appleton I, Moore AR, et al. Cyclo-cxygenase and nitric oxide synthase isoform in rat carrageenin-induced pleurisy. Br J Pharmacol, 1994, 113: 693-698
50. Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA, 1994, 91(2): 2046-2050
51. Blot WJ, Fischer T, Nielsen GL, et al. Outcome of upper gastro-intestinal bleeding and use of ibuprofen versus paracetamol. Pharm World Sci, 2004, 26(6): 319-323
52. Becker JC, Domschke W, Pohle T. Current approaches to prevent NSAED-induced gastropathy—COX selectivity and beyond. Br J Clin Pharmacol, 2004, 58(6): 587-600
53. Kiefer W, Dannhardt G. Novel insights and therapeutical applications in the field of inhibitors of COX-2. Curr Med Chem, 2004, 11(24): 3147-3161
54. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology, 2004, 127(4): 1038-1043
55. Gibofsky A, Williams GW, McKenna F, et al. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum, 2003, 48(11): 3102-3111
56. Schnitzer TJ, Kong SX, Mitchell JH, et al. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. Clin Ther, 2003, 25(12): 3162-3172
57. Geis GS. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Scand J Rheumatol Suppl, 1999, 109: 31-37
58. Brzozowska I, Targosz A, Sliwowski Z, et al. Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor. J Physiol Pharmacol, 2004, 55(4): 773-790
59. Duan YM, Li ZS, Zhan XB, et al. Changes in endothelin-1 gene expression in the gastric mucosa of rats under cold-restraint-stress. Chin J Dig Dis, 2004, 5(1): 28-34
60. Albino de Almeida AB, Melo PS, Hiruma-Lima CA, et al. Antiulcerogenic effect and cytotoxic activity of semi-synthetic crotonin obtained from Croton cajucara Benth. Eur J Pharmacol, 2003, 472(3): 205-212
61. Swarnakar S, Ganguly K, Kundu P, et al. Curcumin regulates expression and activity of matrix metalloproteinases 9 and 2 during prevention and healing of indomethacin-induced gastric ulcer. J Biol Chem, 2005, 280(10): 9409-9415
62. Chattopadhyay I, Nandi B, Chatterjee R, et al. Mechanism of antiulcer effect of Neem (Azadirachta indica) leaf extract: effect on H+-K+-ATPase, oxidative damage and apoptosis. Inflammopharmacology, 2004, 12(2): 153-176
63.杜群,王汝俊,邵庭荫等.胃炎消颗粒抗实验性胃溃疡的作用.广州中医药大学学报,2004,21(3):191-195
64.刘建平,卜涛,白建乐等.EGF、TGF-α及EGFR在大鼠胃溃疡自愈过程中的表达及意义.中国药理学通报,2003,19(10):1185-1188
65. Motilva V, Alarcon de la Lastra C, Bruseghini L, et al. COX expression and PGE(2) and PGD(2) production in experimental acute and chronic gastric lesions. Int Immunopharmacol, 2005, 5(2): 369-379
66. Liu CM, Hong CY, Shun CT, et al. Inducible cyclooxygenase and interleukin 6 gene expressions in nasal polyp fibroblasts: possible implication in the pathogenesis of nasal polyposis. Arch Otolaryngol Head Neck Surg, 2002, 128(8): 945-951
67. Fehrenbacher JC, Burkey TH, Nicol GD, et al. Tumor necrosis factor alpha and interleukin-lbeta stimulate the expression of cyclooxygenase Ⅱ but do not alter prostaglandin E2 receptor mRNA levels in cultured dorsal root ganglia cells. Pain, 2005, 113(1-2): 113-122
68. Kargman S, Charleson S, Cartwright M, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology, 1996, 114:445
69. Chan CC, Boyce S, Brideau C, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745, 337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther, 1995, 274: 1531-1537
70. Yeomans ND. Management of peptic ulcer disease not related to Helicobacter. J Gastroenterol Hepatol, 2002, 17(4): 488-494
71. Onizuka Y, Murase K, Furusu H, et al. Effect of intrarectal prostaglandin E2 analogue (enprostil) on trinitrobenzenesulphonic acid-induced colitis in rats. J Int Med Res, 2000, 28(1): 28-35
72. Bardhan KD, Bishop AE, Polak JM, et al. Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment. Dig Liver Dis, 2005, 37(1): 10-22
73. Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol, 2005, 3(1): 39-48.
74. Ilnyckyj A, Mathew G. Management of acute bleeding upper gastrointestinal ulcers in the era of endoscopic and intravenous proton pump inhibitor therapy. Can J Gastroenterol, 2005, 19(3): 157-159
75. Robinson M. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders. Aliment Pharmacol Ther, 2004, 20 Suppl 6: 30-37
76. Bandyopadhyay U, Biswas K, Sengupta A, et al. Clinical studies on the effect of Neem (Azadirachta indica) bark extract on gastric secretion and gastroduodenal ulcer. Life Sci, 2004, 75(24): 2867-2878
77. Miller ML, Judd LM, Van Driel IR, et al. The unique ultrastructure of secretory membranes in gastric parietal cells depends upon the presence of H+, K+ -ATPase. Cell Tissue Res, 2002, 309(3): 369-380
78. Cgata T, Yamasaki Y. Morphological studies on the translocation of tubulovesicular system toward the intracellular canaliculi during stimulation of the gastric parietal cell. Microsc Res Tech, 2000, 48(5): 282-292
79. Tari A, Kawano M, Kodama K, et al. The effects of rabeprazole on parietal cells and enterochromaffin-like cells in rats: a comparison with omeprazole. J Gastroenterol, 2002, 37(3): 177-185
80. Chen MC, Amirian DA, Toomey M, et al. Prostanoid inhibition of canine parietal cells: mediation by the inhibitory guanosine triphosphate-binding protein of adenylate cyclase. Gastroenterology, 1988, 94(5 Pt 1):1121-1129
81. Hakanson R, Chen D, Lindstrom E, et al. Control of secretion from rat stomach ECL cells in situ and in primary culture. Scand J Clin Lab Invest Suppl, 2001, (234): 53-60
82. Lindstrom E, Hakanson R. Neurohormonal regulation of secretion from isolated rat stomach ECL cells: a critical reappraisal. Regul Pept, 2001, 97(2-3): 169-180
83. Norlen P, Bernsand M, Konagaya T, et al. ECL-cell histamine mobilization in conscious rats: effects of locally applied regulatory peptides, candidate neurotransmitters and inflammatory mediators. Br J Pharmacol, 2001, 134(8): 1767-1777
84. Tarnawski A. Cellular mechanisms of gastric ulcer healing. Domschke W Konturek SJ eds. The Stomach. New York, Springer-Verlag, Berlin, 1993, PP 177-192
85. Shin VY, Liu ES, Ye YN, et al. A mechanistic study of cigarette smoke and cyclooxygenase-2 on proliferation of gastric cancer cells. Toxicol Appl Pharmacol, 2004, 195(1): 103-112
86. Yu HP, Shi LY, Lu WH, et al. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398. J Gastroenterol Hepatol, 2004, 19(6): 638-642
87. Zhang ZH, Ouyang Q, Gan HT. Targeting cyclooxygenase-2 with sodium butyrate and NSAIDs on colorectal adenoma/carcinoma cells. World J Gastroenterol, 2004, 10(20): 2954-2957
88. Evans JF, Kargman SL. Cancer and cyclooxygenase-2 (COX-2) inhibition. Curr Pharm Des, 2004, 10(6): 627-634
89. Kern MA, Schoneweiss MM, Sahi D, Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis, 2004, 25(7): 1193-1199
90. Xue WC, Khoo US, Ngan HY, et al. Minichromosome maintenance protein 7 expression in gestational trophoblastic disease: correlation with Ki67, PCNA and clinicopathological parameters. Histopathology, 2003, 43(5): 485-490
91. Muskhelishvili L, Latendresse JR, Kodell RL, et al. Evaluation of cell proliferation in rat tissues with BrdU, PCNA, Ki-67 (MIB-5) immunohistochemistry and in situ hybridization for histone mRNA. J Histochem Cytochem, 2003, 51(12): 1681-1688
92. Gruber A, Schmidt P, Url A. Immunohistochemical studies concerning the neuronal cell cycle of the cat using PCNA, Ki-67 and p53 markers. J Vet Med A Physiol Pathol Clin Med, 2004, 51(9-10): 416-419
93. Churin Y, Al-Ghoul L, Kepp O, et al. Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response. J Cell Biol, 2003, 161(2): 249-255
94. Cacci E, Salani M, Anastasi S, et al. Hepatocyte growth factor stimulates cell motility in cultures of the striatal progenitor cells ST14A. J Neurosci Res, 2003, 74(5): 760-768
95. Karihaloo A, Kale S, Rosenblum ND, et al. Hepatocyte growth factor-mediated renal epithelial branching morphogenesis is regulated by glypican-4 expression. Mol Cell Biol, 2004, 24(19): 8745-8752
96. Carrington LM, Boulton M. Hepatocyte growth factor and keratinocyte growth factor regulation of epithelial and stromal corneal wound healing. J Cataract Refract Surg, 2005, 31(2): 412-423
97. Oh K, Iimuro Y, Takeuchi M, et al. Ameliorating effect of hepatocyte growth factor on inflammatory bowel disease in a murine model. : Am J Physiol Gastrointest Liver Physiol, 2005, 288(4): G729-735
98. Hori T, Ido A, Uto H, et al. Activation of hepatocyte growth factor in monkey stomach following gastric mucosal injury. J Gastroenterol, 2004, 39(2): 133-139
99. Netzer P, Halter F, Ma TY, et al. Interaction of hepatocyte growth factor and non-steroidal anti-inflammatory drugs during gastric epithelial wound healing. Digestion, 2003, 67(3): 118-128
100. Takahashi M, Katayama Y, Takada H, et al. The effect of NSAIDs and a COX-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGF in human gastric fibroblasts. Aliment Pharmacol Ther, 2000, 14 Suppl 1:44-49
101.Luo JC, Shin VY, Liu ES, et al. Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs. Eur J Pharmacol, 2004, 485(1-3): 275-281
102.Yao M, Zhou W, Sangha S, et al. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res, 2005, 11(4): 1618-1628
103.Wei D, Wang L, He Y, et al. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res, 2004, 64(6): 2030-2038
104.Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci, 2003, 44(1): 409-415
105.Trojan L, Thomas D, Friedrich D, et al. Expression of different vascular endothelial markers in prostate cancer and BPH tissue: an immunohistochemical and clinical evaluation. Anticancer Res, 2004, 24(3a): 1651-1656
106.Bialas M, Okon K, Czopek J. Assessing microvessel density in gastric carcinoma: a comparison of three markers. Pol J Pathol, 2003, 54(4): 249-252
107. Ichinoe M, Mikami T, Shiraishi H, et al. High microvascular density is correlated with high VEGF, iNOS and COX-2 expression in penetrating growth-type early gastric carcinomas. Histopathology, 2004,45(6): 612-618
108. Delrieu I. The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism. FEBS Lett, 2000, 18: 6-10
109.Komori M, Tomizawa Y, Takada K, et al. A single local application of recombinant human basic fibroblast growth factor accelerates initial angiogenesis during wound healing in rabbit ear chamber. Anesth Analg, 2005, 100(3): 830-834
110. Jee SH, Chu CY, Chiu HC, et al. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Invest Dermatol, 2004, 123(6): 1169-1175
111. Ernst H, Konturek, PC, Hahn EG, et al. Effect of local injection with basic fibroblast growth factor (BFGF) and neutralizing antibody to BFGF on gastric ulcer healing, gastric secretion, angiogenesis and gastric blood flow. J Physiol. Pharmacol, 2001, 52, 377-390
112.Gray JJ, Bickler PE, Fahlman CS, et al. Isoflurane neuroprotection in hypoxic hippocampal slice cultures involves increases in intracellular Ca2+ and mitogen-activated protein kinases. Anesthesiology, 2005, 102(3): 606-615
113.Millette E, Rauch BH, Defawe O, et al. Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR-1 activation. Circ Res, 2005, 96(2): 172-179
114.Liu Y, Suzuki YJ, Day RM, et al. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res, 2004, 95(6): 579-586
115.Pai R, Jones MK, Tomikawa M, et al. Activation of Raf-1 during experimental gastric ulcer healing is Ras-mediated and protein kinase C-independent. Am J Pathol, 1999, 155(5): 1759-1766
116.Tarnawski AS, Pai R, Wang H, Translocation of MAP (Erk-1 and -2) kinases to cell nuclei and activation of c-fos gene during healing of experimental gastric ulcers. J Physiol Pharmacol, 1998, 49(4): 479-488
117.Bao YL, Tsuchida K, Liu B, et al. Synergistic activity of activin A and basic fibroblast growth factor on tyrosine hydroxylase expression through Smad3 and ERK1/ERK2 MAPK signaling pathways. J Endocrinol, 2005, 184(3): 493-504
118.Thompson J, Dolcet X, Hilton M, et al. HGF promotes survival and growth of maturing sympathetic neurons by PI-3 kinase- and MAP kinase-dependent mechanisms. Mol Cell Neurosci, 2004, 27(4): 441-452.
2. Kim KM, Oh YL, Ko JS, et al. Histopathology and expression of Ki-67 and cyclooxygenase-2 in childhood Helicobacter pylori gastritis. J Gastroenterol, 2004, 39(3): 231-237
3. Kuo CL, Chi CW, Liu TY. Modulation of apoptosis by berberine through inhibition of cyclooxygenase-2 and Mcl-1 expression in oral cancer cells. In Vivo, 2005, 19(1): 247-252
4. Tibble J, Sigthorsson G, Caldwell C, et al. Effects of NSAIDs on cryoprobe-induced gastric ulcer healing in rats. Aliment Pharmacol Ther, 2001, 15(12): 2001-2008
5. Peura DA. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med, 2004, 117 Suppl 5A: 63S-71S
6. Gajraj NM, Joshi GP. Role of cyclooxygenase-2 inhibitors in postoperative pain management. Anesthesiol Clin North America, 2005, 23(1): 49-72
7. Stephens JM, Pashos CL, Haider S, et al. Making progress in the management of postoperative pain: a review of the cyclooxygenase 2-specific inhibitors. Pharmacotherapy, 2004, 24(12): 1714-1731
8. Qadri SS, Wang JH, Coffey JC, et al. Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition. Ann Thorac Surg, 2005, 79(3): 990-995
9. Tanaka T, Delong PA, Amin K, et al. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery. Ann Surg, 2005, 241(1): 168-178
10. Graham P, Pidgeon GP, Tamosiuniene R, et al. Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation, 2004, 110(17): 2701-2707
11. Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum, 2002, 32(3 Suppl 1): 25-32
12. Schmassmann A, Peskar BM, Stettler C, et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol, 1998, 123(5): 795-804
13. Giap AQ, Tarnawski A, Hoa NT, et al. NSAID inhibition of RGM1 gastric monolayer wound re-epithelialization: comparison of selective Cox-2 versus non-selective Cox inhibitors. Life Sci, 2002, 70(25): 3029-3037
14. Berenguer B, Alarcon de la Lastra C, Moreno FJ. Chronic gastric ulcer healing in rats subjected to selective and non-selective cyclooxygenase-2 inhibitors. Eur J Pharmacol, 2002; 442(1-2): 125-135
15. Helander HF, Weijdegard B, Bamberg K, et al. The expression of pepsinogen c mRNA in normal gastroduodenal mucosa and the gastric ulcer margin of the rat. Histochem Cell Biol, 1996, 105(2): 163-169
16. Kazumori H, Ishihara S, Fukuda R. Time-course changes of ECL cell markers in acetic acid-induced gastric ulcers in rats. Aliment Pharmacol Ther, 2002, 16 Suppl 2: 10-19
17. Tsukimi Y, Nakai H, Itoh S, et al. Involvement of heat shock proteins in the healing of acetic acid-induced gastric ulcers in rats. J Physiol Pharmacol, 2001, 52(3): 391-406
18. Konturek PC. Brzozowski T, Sulekova Z, et al. Role of leptin in ulcer healing. Eur J Pharmacol, 2001, 414(1): 87-97
19. Nguyen NV, Gleeson PA, Courtois-Coutry N, et al. Gastric parietal cell acid secretion in mice can be regulated independently of H/K ATPase endocytosis. Gastroenterology, 2004, 127(1): 145-154
20. Barocelli E, Ballabeni V. Histamine in the control of gastric acid secretion: a topic review. Pharmacol Res, 2003,47(4): 299-304
21. Chen D, Zhao CM, Hakanson R, et al. Altered control of gastric acid secretion in gastrin-cholecystokinin double mutant mice. Gastroenterology, 2004, 126(2): 476-487
22. Fykse V, Coy DH, Waldum HL, et al. Somatostatin-receptor 2 (sst2)-mediated effects of endogenous somatostatin on exocrine and endocrine secretion of the rat stomach. Br J Pharmacol, 2005, 144(3): 416-421
23. Beales IL, Calam J. Inhibition of carbachol stimulated acid secretion by interleukin 1beta in rabbit parietal cells requires protein kinase C. Gut, 2001, 48(6): 782-789
24. Schmassmann A, Stettler C, Poulsom R, et al. Roles of hepatocyte growth factor and its receptor Met during gastric ulcer healing in rats. Gastroenterology, 1997, 113(6): 1858-1872
25. Ma L, Chow JY, Wong BC, et al. Role of capsaicin sensory nerves and EGF in the healing of gastric ulcer in rats. Life Sci, 2000, 66(15): PL213-220
26. Gonul B, Akbulut KG, Ozer C, et al. The role of transforming growth factor alpha formulation on aspirin-induced ulcer healing and oxidant stress in the gastric mucosa. Surg Today, 2004, 34(12): 1035-1040
27. Hori K, Shiota G, Kawasaki H. Expression of hepatocyte growth factor and c-met receptor in gastric mucosa during gastric ulcer healing. Scand J Gastroenterol, 2000,35(1):23-31
28. Brzozowski T, Konturek PC, Konturek SJ, et al. Effect of local application of growth factors on gastric ulcer healing and mucosal expression of cyclooxygenase-1 and -2. Digestion, 2001, 64(1): 15-29
29. Szabo S, Khomenko T, Gombos Z, et al. Review article: transcription factors and growth factors in ulcer healing. Aliment Pharmacol Ther, 2000, 14 Suppl 1: 33-43
30. Shih SC, Tseng KW, Lin SC, et al. Expression patterns of transforming growth factor-beta and its receptors in gastric mucosa of patients with refractory gastric ulcer. World J Gastroenterol, 2005, 11(1): 136-141
31. Szabo S, Vincze A. Growth factors in ulcer healing: lessons from recent studies. J Physiol Paris, 2000, 94(2): 77-81
32. Li DY, Zhao K, Zhou JF, et al. Changes of expressions of VEGE bFGF, and angiogenesis, and effect of benazepril, bFGF on angiogenesis in acute myocardial infarction model of the rabbits. Biomed Environ Sci, 2004, 17(4): 442-451
33. Shin HY, Schwartz EA, Bizios R, et al. Receptor-mediated basic fibroblast growth factor signaling regulates cyclic pressure-induced human endothelial cell proliferation. Endothelium, 2004, 11 (5-6): 285-291
34. Kawanaka H, Tomikawa M, Jones MK, et al. Portal hypertensive gastric mucosa has reduced activation of MAP kinase (ERK2) in response to alcohol injury: a key to impaired healing? FASEB J, 2001, 15(3): 574-576
35. Pai R, Ohta M, Itani RM, et al. Induction of mitogen-activated protein kinase signal transducfion pathway during gastric ulcer healing in rats. Gastroenterology, 1998, 114(4): 706-713
36. Schmassmann A. Mechanisms of ulcer healing and effects of nonsteroidal anti-inflammatory drugs. Am J Med, 1998, 104(3A): 43S-51S
37. Brzozowski T. Experimental production of peptic ulcer, gastric damage and cancer models and their use in pathophysiological studies and pharmacological treatment-Polish achievements. J Physiol Pharmacol, 2003, 54 Suppl 3: 99-126
38. Wallace JL, Chapman K, McKnight W. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol, 1999, 126: 1200-1204
39.孙凤蓬,宋于刚,朱新生等.冰乙酸性大鼠胃溃疡模型制作及溃疡自愈过程中胃窦的组织学.第一军医大学学报,200l,21(8):578-581
40. Calabro A, Grappone C, Pellegrini G; et al. Spatial and temporal pattern of expression of interstitial collagenase, stromelysin/transin, gelatinase A, and TIMP-1 during experimental gastric ulcer healing. Digestion, 2004, 70(2): 127-138
41. Kim JS, Kim JM, Jung HC, et al. Helicobacter pylori down-regulates the receptors of vascular endothelial growth factor and angiopoietin in vascular endothelial cells: implications in the impairment of gastric ulcer healing. Dig Dis Sci, 2004, 49(5): 778-786
42.朱立,杨宗诚,黎螯等.大鼠严重烧伤早期胃酸分泌功能改变的机制及其在急性胃粘膜损害防治中的意义.中华普通外科杂志,2000,15(2):88-90
43.郭津生,古永亮,王吉耀等.环氧化酶异构酶在大鼠胃溃疡模型中的表达和活性变化.中华医学杂志,2001,81(24):1519-1522
44. Tsujii M, Kawano S, Tsuji S, et al. Cell kinetics of mucosal atrophy in rat stomach induced by long-term administration of ammonia. Gastroenterology, 1993, 104(3): 796-801
45.叶秀锦,王丽君,林茂芳等.急性白血病患者骨髓血管新生的研究及临床意义.中华内科杂志,2003,42(7):486-489
46. Chung NA, Beevers DG Lip G. Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. Blood Press, 2004, 13(3): 183-189
47. Yang DH, Tsuyama S, Murata E The expression of gastric H+-K+-ATPase mRNA and protein in developing rat fundic gland. Histochem J, 2001, 33(3): 159-166
48. de Groot M, Schuurs TA, Leuvenink HG, et al. Macrophage overgrowth affects neighboring nonovergrown encapsulated islets. J Surg Res, 2003, 115(2): 235-241
49. Tomlinson A, Appleton I, Moore AR, et al. Cyclo-cxygenase and nitric oxide synthase isoform in rat carrageenin-induced pleurisy. Br J Pharmacol, 1994, 113: 693-698
50. Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA, 1994, 91(2): 2046-2050
51. Blot WJ, Fischer T, Nielsen GL, et al. Outcome of upper gastro-intestinal bleeding and use of ibuprofen versus paracetamol. Pharm World Sci, 2004, 26(6): 319-323
52. Becker JC, Domschke W, Pohle T. Current approaches to prevent NSAED-induced gastropathy—COX selectivity and beyond. Br J Clin Pharmacol, 2004, 58(6): 587-600
53. Kiefer W, Dannhardt G. Novel insights and therapeutical applications in the field of inhibitors of COX-2. Curr Med Chem, 2004, 11(24): 3147-3161
54. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology, 2004, 127(4): 1038-1043
55. Gibofsky A, Williams GW, McKenna F, et al. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum, 2003, 48(11): 3102-3111
56. Schnitzer TJ, Kong SX, Mitchell JH, et al. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. Clin Ther, 2003, 25(12): 3162-3172
57. Geis GS. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Scand J Rheumatol Suppl, 1999, 109: 31-37
58. Brzozowska I, Targosz A, Sliwowski Z, et al. Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor. J Physiol Pharmacol, 2004, 55(4): 773-790
59. Duan YM, Li ZS, Zhan XB, et al. Changes in endothelin-1 gene expression in the gastric mucosa of rats under cold-restraint-stress. Chin J Dig Dis, 2004, 5(1): 28-34
60. Albino de Almeida AB, Melo PS, Hiruma-Lima CA, et al. Antiulcerogenic effect and cytotoxic activity of semi-synthetic crotonin obtained from Croton cajucara Benth. Eur J Pharmacol, 2003, 472(3): 205-212
61. Swarnakar S, Ganguly K, Kundu P, et al. Curcumin regulates expression and activity of matrix metalloproteinases 9 and 2 during prevention and healing of indomethacin-induced gastric ulcer. J Biol Chem, 2005, 280(10): 9409-9415
62. Chattopadhyay I, Nandi B, Chatterjee R, et al. Mechanism of antiulcer effect of Neem (Azadirachta indica) leaf extract: effect on H+-K+-ATPase, oxidative damage and apoptosis. Inflammopharmacology, 2004, 12(2): 153-176
63.杜群,王汝俊,邵庭荫等.胃炎消颗粒抗实验性胃溃疡的作用.广州中医药大学学报,2004,21(3):191-195
64.刘建平,卜涛,白建乐等.EGF、TGF-α及EGFR在大鼠胃溃疡自愈过程中的表达及意义.中国药理学通报,2003,19(10):1185-1188
65. Motilva V, Alarcon de la Lastra C, Bruseghini L, et al. COX expression and PGE(2) and PGD(2) production in experimental acute and chronic gastric lesions. Int Immunopharmacol, 2005, 5(2): 369-379
66. Liu CM, Hong CY, Shun CT, et al. Inducible cyclooxygenase and interleukin 6 gene expressions in nasal polyp fibroblasts: possible implication in the pathogenesis of nasal polyposis. Arch Otolaryngol Head Neck Surg, 2002, 128(8): 945-951
67. Fehrenbacher JC, Burkey TH, Nicol GD, et al. Tumor necrosis factor alpha and interleukin-lbeta stimulate the expression of cyclooxygenase Ⅱ but do not alter prostaglandin E2 receptor mRNA levels in cultured dorsal root ganglia cells. Pain, 2005, 113(1-2): 113-122
68. Kargman S, Charleson S, Cartwright M, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology, 1996, 114:445
69. Chan CC, Boyce S, Brideau C, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745, 337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther, 1995, 274: 1531-1537
70. Yeomans ND. Management of peptic ulcer disease not related to Helicobacter. J Gastroenterol Hepatol, 2002, 17(4): 488-494
71. Onizuka Y, Murase K, Furusu H, et al. Effect of intrarectal prostaglandin E2 analogue (enprostil) on trinitrobenzenesulphonic acid-induced colitis in rats. J Int Med Res, 2000, 28(1): 28-35
72. Bardhan KD, Bishop AE, Polak JM, et al. Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment. Dig Liver Dis, 2005, 37(1): 10-22
73. Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol, 2005, 3(1): 39-48.
74. Ilnyckyj A, Mathew G. Management of acute bleeding upper gastrointestinal ulcers in the era of endoscopic and intravenous proton pump inhibitor therapy. Can J Gastroenterol, 2005, 19(3): 157-159
75. Robinson M. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders. Aliment Pharmacol Ther, 2004, 20 Suppl 6: 30-37
76. Bandyopadhyay U, Biswas K, Sengupta A, et al. Clinical studies on the effect of Neem (Azadirachta indica) bark extract on gastric secretion and gastroduodenal ulcer. Life Sci, 2004, 75(24): 2867-2878
77. Miller ML, Judd LM, Van Driel IR, et al. The unique ultrastructure of secretory membranes in gastric parietal cells depends upon the presence of H+, K+ -ATPase. Cell Tissue Res, 2002, 309(3): 369-380
78. Cgata T, Yamasaki Y. Morphological studies on the translocation of tubulovesicular system toward the intracellular canaliculi during stimulation of the gastric parietal cell. Microsc Res Tech, 2000, 48(5): 282-292
79. Tari A, Kawano M, Kodama K, et al. The effects of rabeprazole on parietal cells and enterochromaffin-like cells in rats: a comparison with omeprazole. J Gastroenterol, 2002, 37(3): 177-185
80. Chen MC, Amirian DA, Toomey M, et al. Prostanoid inhibition of canine parietal cells: mediation by the inhibitory guanosine triphosphate-binding protein of adenylate cyclase. Gastroenterology, 1988, 94(5 Pt 1):1121-1129
81. Hakanson R, Chen D, Lindstrom E, et al. Control of secretion from rat stomach ECL cells in situ and in primary culture. Scand J Clin Lab Invest Suppl, 2001, (234): 53-60
82. Lindstrom E, Hakanson R. Neurohormonal regulation of secretion from isolated rat stomach ECL cells: a critical reappraisal. Regul Pept, 2001, 97(2-3): 169-180
83. Norlen P, Bernsand M, Konagaya T, et al. ECL-cell histamine mobilization in conscious rats: effects of locally applied regulatory peptides, candidate neurotransmitters and inflammatory mediators. Br J Pharmacol, 2001, 134(8): 1767-1777
84. Tarnawski A. Cellular mechanisms of gastric ulcer healing. Domschke W Konturek SJ eds. The Stomach. New York, Springer-Verlag, Berlin, 1993, PP 177-192
85. Shin VY, Liu ES, Ye YN, et al. A mechanistic study of cigarette smoke and cyclooxygenase-2 on proliferation of gastric cancer cells. Toxicol Appl Pharmacol, 2004, 195(1): 103-112
86. Yu HP, Shi LY, Lu WH, et al. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398. J Gastroenterol Hepatol, 2004, 19(6): 638-642
87. Zhang ZH, Ouyang Q, Gan HT. Targeting cyclooxygenase-2 with sodium butyrate and NSAIDs on colorectal adenoma/carcinoma cells. World J Gastroenterol, 2004, 10(20): 2954-2957
88. Evans JF, Kargman SL. Cancer and cyclooxygenase-2 (COX-2) inhibition. Curr Pharm Des, 2004, 10(6): 627-634
89. Kern MA, Schoneweiss MM, Sahi D, Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis, 2004, 25(7): 1193-1199
90. Xue WC, Khoo US, Ngan HY, et al. Minichromosome maintenance protein 7 expression in gestational trophoblastic disease: correlation with Ki67, PCNA and clinicopathological parameters. Histopathology, 2003, 43(5): 485-490
91. Muskhelishvili L, Latendresse JR, Kodell RL, et al. Evaluation of cell proliferation in rat tissues with BrdU, PCNA, Ki-67 (MIB-5) immunohistochemistry and in situ hybridization for histone mRNA. J Histochem Cytochem, 2003, 51(12): 1681-1688
92. Gruber A, Schmidt P, Url A. Immunohistochemical studies concerning the neuronal cell cycle of the cat using PCNA, Ki-67 and p53 markers. J Vet Med A Physiol Pathol Clin Med, 2004, 51(9-10): 416-419
93. Churin Y, Al-Ghoul L, Kepp O, et al. Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response. J Cell Biol, 2003, 161(2): 249-255
94. Cacci E, Salani M, Anastasi S, et al. Hepatocyte growth factor stimulates cell motility in cultures of the striatal progenitor cells ST14A. J Neurosci Res, 2003, 74(5): 760-768
95. Karihaloo A, Kale S, Rosenblum ND, et al. Hepatocyte growth factor-mediated renal epithelial branching morphogenesis is regulated by glypican-4 expression. Mol Cell Biol, 2004, 24(19): 8745-8752
96. Carrington LM, Boulton M. Hepatocyte growth factor and keratinocyte growth factor regulation of epithelial and stromal corneal wound healing. J Cataract Refract Surg, 2005, 31(2): 412-423
97. Oh K, Iimuro Y, Takeuchi M, et al. Ameliorating effect of hepatocyte growth factor on inflammatory bowel disease in a murine model. : Am J Physiol Gastrointest Liver Physiol, 2005, 288(4): G729-735
98. Hori T, Ido A, Uto H, et al. Activation of hepatocyte growth factor in monkey stomach following gastric mucosal injury. J Gastroenterol, 2004, 39(2): 133-139
99. Netzer P, Halter F, Ma TY, et al. Interaction of hepatocyte growth factor and non-steroidal anti-inflammatory drugs during gastric epithelial wound healing. Digestion, 2003, 67(3): 118-128
100. Takahashi M, Katayama Y, Takada H, et al. The effect of NSAIDs and a COX-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGF in human gastric fibroblasts. Aliment Pharmacol Ther, 2000, 14 Suppl 1:44-49
101.Luo JC, Shin VY, Liu ES, et al. Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs. Eur J Pharmacol, 2004, 485(1-3): 275-281
102.Yao M, Zhou W, Sangha S, et al. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res, 2005, 11(4): 1618-1628
103.Wei D, Wang L, He Y, et al. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res, 2004, 64(6): 2030-2038
104.Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci, 2003, 44(1): 409-415
105.Trojan L, Thomas D, Friedrich D, et al. Expression of different vascular endothelial markers in prostate cancer and BPH tissue: an immunohistochemical and clinical evaluation. Anticancer Res, 2004, 24(3a): 1651-1656
106.Bialas M, Okon K, Czopek J. Assessing microvessel density in gastric carcinoma: a comparison of three markers. Pol J Pathol, 2003, 54(4): 249-252
107. Ichinoe M, Mikami T, Shiraishi H, et al. High microvascular density is correlated with high VEGF, iNOS and COX-2 expression in penetrating growth-type early gastric carcinomas. Histopathology, 2004,45(6): 612-618
108. Delrieu I. The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism. FEBS Lett, 2000, 18: 6-10
109.Komori M, Tomizawa Y, Takada K, et al. A single local application of recombinant human basic fibroblast growth factor accelerates initial angiogenesis during wound healing in rabbit ear chamber. Anesth Analg, 2005, 100(3): 830-834
110. Jee SH, Chu CY, Chiu HC, et al. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Invest Dermatol, 2004, 123(6): 1169-1175
111. Ernst H, Konturek, PC, Hahn EG, et al. Effect of local injection with basic fibroblast growth factor (BFGF) and neutralizing antibody to BFGF on gastric ulcer healing, gastric secretion, angiogenesis and gastric blood flow. J Physiol. Pharmacol, 2001, 52, 377-390
112.Gray JJ, Bickler PE, Fahlman CS, et al. Isoflurane neuroprotection in hypoxic hippocampal slice cultures involves increases in intracellular Ca2+ and mitogen-activated protein kinases. Anesthesiology, 2005, 102(3): 606-615
113.Millette E, Rauch BH, Defawe O, et al. Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR-1 activation. Circ Res, 2005, 96(2): 172-179
114.Liu Y, Suzuki YJ, Day RM, et al. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res, 2004, 95(6): 579-586
115.Pai R, Jones MK, Tomikawa M, et al. Activation of Raf-1 during experimental gastric ulcer healing is Ras-mediated and protein kinase C-independent. Am J Pathol, 1999, 155(5): 1759-1766
116.Tarnawski AS, Pai R, Wang H, Translocation of MAP (Erk-1 and -2) kinases to cell nuclei and activation of c-fos gene during healing of experimental gastric ulcers. J Physiol Pharmacol, 1998, 49(4): 479-488
117.Bao YL, Tsuchida K, Liu B, et al. Synergistic activity of activin A and basic fibroblast growth factor on tyrosine hydroxylase expression through Smad3 and ERK1/ERK2 MAPK signaling pathways. J Endocrinol, 2005, 184(3): 493-504
118.Thompson J, Dolcet X, Hilton M, et al. HGF promotes survival and growth of maturing sympathetic neurons by PI-3 kinase- and MAP kinase-dependent mechanisms. Mol Cell Neurosci, 2004, 27(4): 441-452.